• Difficulties in Calculating Productivity Costs- Work Disability Associated with Borderline Personality Disorder

    Jul 1, 2008, 00:00

  • Deterioration of Quality of Life of High-Risk Breast Cancer Patients Treated with High-Dose Chemotherapy- The PEGASE 01 Quality of Life Study

    Jul 1, 2008, 00:00

  • Clustering of Cardiovascular Disease Risk Factors and Health-Related Quality of Life among US Adults

    Jul 1, 2008, 00:00

  • The Hanover Consensus- Helpful for German Decision-Makers?

    Jul 1, 2008, 00:00

  • Service Utilization and Health-Care Costs in the Advanced Elderly

    Jul 1, 2008, 00:00

  • Development of EMPRO- A Tool for the Standardized Assessment of Patient-Reported Outcome Measures

    Jul 1, 2008, 00:00

  • Health-Related Quality of Life Measures for Children and Adolescents with Epilepsy- A Response to Comments

    Jul 1, 2008, 00:00

  • Psychometric Validation of the Cancer Therapy Satisfaction Questionnaire

    Jul 1, 2008, 00:00

  • Understanding Medication Compliance and Persistence from an Economics Perspective

    Jul 1, 2008, 00:00

  • The Effect of Perceived Health Status on Patient Satisfaction

    Jul 1, 2008, 00:00

  • Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease

    Jul 1, 2008, 00:00

  • Scientific Guidelines and Their Implementation in Health Policy

    Jul 1, 2008, 00:00

  • Factorial Invariance of Child Self-Report across Age Subgroups- A Confirmatory Factor Analysis of Ages 5 to 16 Years Utilizing the PedsQL 4.0 Generic Core Scales

    Jul 1, 2008, 00:00

  • Preference-Based Quality of Life of Patients on Renal Replacement Therapy- A Systematic Review and Meta-Analysis

    Jul 1, 2008, 00:00

  • The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making- To Lambda and Beyond

    Jul 1, 2008, 00:00

  • Cost-Effectiveness Model for Neovascular Age-Related Macular Degeneration- Comparing Early and Late Treatment with Pegaptanib Sodium Based on Visual Acuity

    Jul 1, 2008, 00:00

  • German Recommendations on Health Economic Evaluation- Third and Updated Version of the Hanover Consensus

    Jul 1, 2008, 00:00

  • Introducing Evidence-Based Medicine in Reimbursement Procedures- Does It Affect the Outcome?

    Jul 1, 2008, 00:00

  • Comments on Health-Related Quality of Life Measures for Children and Adolescents with Epilepsy

    Jul 1, 2008, 00:00

  • A Cost-Benefit Analysis Using Contingent Valuation Techniques- A Feasibility Study in Spinal Surgery

    Jul 1, 2008, 00:00

  • Validity, Responsiveness, and Minimal Important Difference for the SF-6D Health Utility Scale in a Spinal Cord Injured Population

    Jul 1, 2008, 00:00

  • The Direct Medical Costs of Undiagnosed Chronic Obstructive Pulmonary Disease

    Jul 1, 2008, 00:00

  • A Randomized Controlled Trial of the Cost-Utility of Second-Generation Antipsychotics in People with Psychosis and Eligible for Clozapine

    Jul 1, 2008, 00:00

  • Economic Burden of Adult Pharyngitis- The Payer's Perspective

    Jul 1, 2008, 00:00

  • Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands

    Jul 1, 2008, 00:00

  • Health-Related Quality of Life Measurement in Children and Adolescents- A Systematic Review of Generic and Disease-Specific Instruments

    Jul 1, 2008, 00:00

  • The KIDSCREEN-52 Quality of Life Measure for Children and Adolescents- Psychometric Results from a Cross-Cultural Survey in 13 European Countries

    Jul 1, 2008, 00:00

  • Survey Assessment of Continuation of and Satisfaction with Pharmacological Treatment for Urinary Incontinence

    Jul 1, 2008, 00:00

  • PSY3 A META-ANALYSIS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OFTHE EFFICACY OF BOTULINUM TOXIN A FOR THE PROPHYLAXIS OF CHRONIC MIGRAINE HEADACHES

    May 1, 2008, 00:00

  • PMC6 THE S ORIGINAL PAPER WITH AN EYE TOTHE FUTURE

    May 1, 2008, 00:00

  • PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE- COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA

    May 1, 2008, 00:00

  • PMS33 RELATIONSHIP BETWEEN PATIENTS COMPLIANCE TO MS SPECIALTY MEDICATIONS AND TOTAL HEALTH CARE COSTS

    May 1, 2008, 00:00

  • PCV52 ECONOMIC IMPACT OF A PHYSICIAN-PHARMACIST COLLABORATIVE CARE INTERVENTION IN PRIMARY CARE FOR PATIENTS WITH DYSLIPIDEMIA A CLUSTER-RANDOMISED CONTROLLED TRIAL (TEAM STUDY)

    May 1, 2008, 00:00

  • PMH66 ETHNICITY ANDTHE IMPACT OF HIGHER MEDICATION COPAYMENTS AMONGVETERANS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PMH35 COST-EFFECTIVENESS OF ORALLY DISSOLVING OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA IN THE USA

    May 1, 2008, 00:00

  • PHP43 PHYSICIANS VIEWS REGARDING THE IMPACT OF MEDICARE PART D DRUG COVERAGE FOR DUAL-ELIGIBLE PATIENTS

    May 1, 2008, 00:00

  • PMH55 MEDICATION COMPLIANCE IN THOSE WITH SCHIZOPHRENIA RECEIVING PSYCHIATRIC SERVICES FROM AVETERANS HOSPITAL INTAIWAN

    May 1, 2008, 00:00

  • PDB50 INCREASED HOSPITALIZATIONS BY CHILDREN WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PMH51 A NEW MEASURE OF ADHERENCE-THE DAILY POSSESSION RATIO (DPR)- COMPARISONS WITHTHE MEDICATION POSSESSION RATIO (MPR) IN THE PRESENCE OF MEDICATION SWITCHING ANDTHERAPEUTIC DUPLICATION

    May 1, 2008, 00:00

  • PMC41 MAPPING SF-12 TO EUROQOL EQ-5D PREFERENCE SCORES IN THE SPANISH-SPEAKING HISPANIC COMMUNITY IN THE UNITED STATES

    May 1, 2008, 00:00

  • PDB78 MEASURING THE IMPACT OF AN EDUCATIONAL PROGRAM ON PHYSICIAN PRACTICE PATTERNS- EXPERTMD(tm) CV DIABETES

    May 1, 2008, 00:00

  • The Burden of Ankylosing Spondylitis in Spain

    May 1, 2008, 00:00

  • PND12 COST-EFFECTIVENESS ASSESSMENT OF ANTIEPILEPTIC DRUGS AS ADJUVANTTREATMENTS FOR THE MANAGEMENT OF REFRACTORY PARTIAL SEIZURES IN ADULT MEXICAN PATIENTS

    May 1, 2008, 00:00

  • PCN15 MODELING THE COST IMPACT OF POSSIBLE CROSS-PROTECTION DIFFERENCES OF TWO CERVICAL CANCERVACCINES IN CANADA USING MULTIPLE PROBABILISTIC SENSITIVITY ANALYSIS

    May 1, 2008, 00:00

  • PSY39 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH HEMOPHILIA AND INHIBITORS

    May 1, 2008, 00:00

  • PCV95 IMPACT OF ADOPTION OF NEWANTIHYPERTENSIVE DRUGS ON THE HEALTH CARE UTILIZATION IN HYPERTENSIVE PATIENTS

    May 1, 2008, 00:00

  • PSS35 THE IMPACT OF GLAUCOMA ON QUALITY OF LIFE- COMPARISON WITH THE CHRONIC DISEASES OSTEOPOROSIS. TYPE 2 DIABETES MELLITUS, AND DEMENTIA

    May 1, 2008, 00:00

  • PMS5 WHAT HAPPENED TO VIOXX USERS?

    May 1, 2008, 00:00

  • MD6 INFLUENCE OF MEDICARE CLAIM-PAYING AGENTSS LYMPHOMA PATIENTS

    May 1, 2008, 00:00

  • PHP62 HOW EVIDENCE-BASED AND TIMELY ARE MEDICARE COVERAGE DECISIONS FOR NEWTECHNOLOGIES- AN EMPIRICAL ANALYSIS, 1999-2007

    May 1, 2008, 00:00

  • PSS45 VALUE OF DRIVING FOR PATIENTS WITH GLAUCOMA- WILLINGNESS TO PAY

    May 1, 2008, 00:00

  • PND2 THE FABRY OUTCOME SURVEY (FOS)- A DATABASE OF PROSPECTIVE OBSERVATIONS ONTHE NATURAL HISTORY AND MANAGEMENT OF A RARE DISEASE

    May 1, 2008, 00:00

  • Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making- an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study

    May 1, 2008, 00:00

  • PCN71 SOCIETAL PREFERENCES (UTILITIES) FORADVANCED MELANOMA HEALTH STATES IN THE UNITED KINGDOM (UK) AND AUSTRALIA

    May 1, 2008, 00:00

  • PHC10 AN ASSESSMENT OF HOSPITAL COSTS AND REIMBURSEMENT AMONG TOTAL HIP OR KNEE ARTHROPLASTY PATIENTS IN THE UNITED STATES THAT EXPERIENCE VENOUS THROMBOEMBOLISM

    May 1, 2008, 00:00

  • PND33 IMPROVED QUALITY OF LIFE AMONG RELAPSINGREMITTING MULTIPLE SCLEROSIS PATIENTS TREATED LONG-TERM WITH GLATIRAMER ACETATE

    May 1, 2008, 00:00

  • DU5 IMPACT OF FORMULARY RESTRICTIONS ON ADHERENCE TO SECOND GENERATION ANTIPSYCHOTICS

    May 1, 2008, 00:00

  • PND18 HIGHER INPATIENT COSTS AMONG PATIENTS WITH SUBARACHNOID HEMORRHAGE COMPLICATED BY VASOSPASM

    May 1, 2008, 00:00

  • PDB45 CANADIAN COST UTILITY ANALYSIS COMPARING EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE TWO DIABETES

    May 1, 2008, 00:00

  • PSY22 COST-EFFECTIVENESS OF PREGABALIN COMPARED TO GABAPENTIN INTREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA

    May 1, 2008, 00:00

  • PHP64 THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE DRG FINANCING OF THE HUNGARIAN HOSPITALS

    May 1, 2008, 00:00

  • PMH62 ASSESSING THE VALIDITY OF DERIVING CLINICAL DEMENTIA RATING (CDR) GLOBAL SCORES FROM INDEPENDENTLY OBTAINED FUNCTIONAL RATING SCALE (FRS) SCORES IN VASCULAR DEMENTIA AND MIXED VASCULAR DEMENTIA PATIENTS

    May 1, 2008, 00:00

  • PND37 REDUCTIONS IN FREQUENCY AND INTENSITY OF PAIN WITH BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PSY24 THE ECONOMIC CONSEQUENCES OF POST OPERATING PAIN MANAGEMENT WITHTRANSDERMAL FENTANYL (IONSYS) VERSUS INTRAVENOUS PATIENT-CONTROLLED ANALGESIA

    May 1, 2008, 00:00

  • PCV41 COMPARISON OF COST-EFFECTIVENESS OF POM (PRESCRIPTION ONLY) STATINS; OTC (OVERTHE COUNTER) STATIN AND PLANT STEROL / STANOL PRODUCTS FOR PRIMARY CVD (CARDIOVASCULAR DISEASE) PREVENTION IN THE UNITED KINGDOM FROM THE PATIENTS PERSPECTI ...

    May 1, 2008, 00:00

  • PM4 EVALUATION OF ATHEORY OF GLOBAL HEALTH PREFERENCE FORMATION

    May 1, 2008, 00:00

  • PCN78 DERIVATION OF UTILITY VALUES FROM EORTC QLQC30 IN LUNG CANCER

    May 1, 2008, 00:00

  • PCN96 REAL WORLD TREATMENT PATTERNS IN HIGH RISK OR METASTATIC MELANOMA- EVIDENCE FROM THE SEER-MEDICARE LINKED DATABASE

    May 1, 2008, 00:00

  • PND35 IMPACT OF NATALIZUMAB ON PATIENT OUTCOMES IN MULTIPLE SCLEROSIS- A CROSS-SECTIONAL SURVEY

    May 1, 2008, 00:00

  • PMH40 TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG MEDICAID PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PDB43 DETERMINANTS OF THE ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE

    May 1, 2008, 00:00

  • PCV28 CARDIOVASCULAR EVENT DRIVEN ECONOMIC ANALYSIS OF ROSUVASTATIN VERSUS SIMVASTATIN USING PRAGMATIC HEAD-TO-HEAD RCTSWITH SURROGATE END-POINT MEASURES

    May 1, 2008, 00:00

  • PMH42 IMPACT OF RISPERIDONE LONG-ACTING INJECTION VERSUS ORAL ANTIPSYCHOTIC TREATMENTS ON HOSPITALIZATION IN SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PRS13 PEDIATRIC ASTHMA- AN EMPLOYER PERSPECTIVE ON ANNUAL EMPLOYEE AND DEPENDENT COSTS FOR MEDICAL CARE AND PRESCRIPTION DRUGS

    May 1, 2008, 00:00

  • PCV85 IMPACT OF MEDICARE PART D IMPLEMENTATION ON STATIN UTILIZATION AND MARKET SHARE IN STATE MEDICAID PROGRAMS

    May 1, 2008, 00:00

  • PND3 TRENDS IN THE PREVALENCE OF AUTISM SPECTRUM DISORDERS AND RELATED HEALTH CARE UTILIZATION AND COSTS IN A STATE MEDICAID PROGRAM

    May 1, 2008, 00:00

  • PHP15 EVALUATING THE USE OF PROVISIONAL PATENTS BYTHE PHARMACEUTICAL INDUSTRY-THE EXPERIENCE OF THE UNITED STATES

    May 1, 2008, 00:00

  • PSS3 COMPARING THE EFFECTIVENESS OF CORTISPORIN VS. CIPRODEX FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2008, 00:00

  • PGI19 DEVELOPMENT OF AN HIV-RELATED, DIARRHEA IMPACT, PATIENT REPORTED OUTCOME (PRO) QUESTIONNAIRE

    May 1, 2008, 00:00

  • A Longitudinal Analysis of Outcomes Associated with Abciximab and Eptifibatide in a Consecutive Series of 3074 Percutaneous Coronary Interventions

    May 1, 2008, 00:00

  • PSS49 HEALTH CARE UTILIZATION INCREASES IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS

    May 1, 2008, 00:00

  • PND30 PERFORMANCE OFTHE EURO QOL 5D (EQ-5D) IN PRIMARY CARE PATIENTS WITH CO-MORBID INSOMNIA

    May 1, 2008, 00:00

  • PMC43 USE OF BACKTRANSLATION REVIEW IN THE TRANSLATION OF PRO INSTRUMENTS-SOME EXAMPLES

    May 1, 2008, 00:00

  • PMC4 THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC EVALUATIONS

    May 1, 2008, 00:00

  • PCV72 ENHANCING THE EFFECTIVENESS OF COMMUNITY STROKE RISK SCREENINGS RANDOMIZED CONTROL TRIAL

    May 1, 2008, 00:00

  • PCV5 THE IMPACT OF PHARMACISTS INTERVENTIONS- SENSITIVITY ON PATIENT OUTCOMES IN HYPERLIPIDEMIA MANAGEMENT

    May 1, 2008, 00:00

  • CV1 EFFECTIVENESS OF COMBINED BETA-BLOCKER AND ACEI OR ARBTHERAPY IN CHRONIC HEART FAILURE

    May 1, 2008, 00:00

  • PSS41 APPLES AND ORANGES? ASSESSING THE RELATIONSHIP BETWEEN HEALTH AND VISION RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PHP13 CONTROLLED SUBSTANCEWASTE IN HOME HOSPICE SETTINGS

    May 1, 2008, 00:00

  • PCV102 THE ASSESSING CARDIOVASCULAR TARGETS (ACT 07) PROGRAM- PRELIMINARY RESULTS FROM A PRACTICE REFLECTIVE ASSESSMENT ACROSS CANADA

    May 1, 2008, 00:00

  • PHP33 HERB/DIETARY SUPPLEMENT AND PRESCRIPTION DRUG USE TRENDS AMONG US ADULTS, 1999-2004

    May 1, 2008, 00:00

  • PUK20 IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE WITH FESOTERODINE- KINGS HEALTH QUESTIONNAIRE ITEM ANALYSIS

    May 1, 2008, 00:00

  • PHP20 PREDICTORS OF ENROLLMENT IN MEDICARE PART D-THE EXPERIENCE OF MEDICARE DRUG DEMONSTRATION PARTICIPANTS WITH RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PMC37 ACCESS TO PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS ANDTHEIR TRANSLATIONS IN THE LIGHT OF FDA RECOMMENDATIONS

    May 1, 2008, 00:00

  • PGI25 COSTS OF A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR ELDERLY (AGE 65) PATIENTS WITH CHRONIC CONSTIPATION IN A MEDICARE PART D POPULATION

    May 1, 2008, 00:00

  • PMH44 HEALTH CARE RESOURCE UTILIZATION AND COSTS COMPARISON FOR MDD PATIENTS ON 10 MG ESCITALOPRAMWHO INCREASED TO 20 MG DOSE VS. THOSEWHOWERE SWITCHED TO SNRI

    May 1, 2008, 00:00

  • PSY42 EFFECTIVENESS OF ONCE-DAILY EXTENDED-RELEASE (ER) TRAMADOL IN ACHIEVING CLINICALLY MEANINGFUL IMPROVEMENT IN FUNCTIONING

    May 1, 2008, 00:00

  • PMH48 BETTER PERSISTENCE ONTREATMENT WITH ESCITALOPRAM COMPARED WITH CITALOPRAM

    May 1, 2008, 00:00

  • PCV84 HEALTH CARE UTILIZATION ASSOCIATED WITH DEPRESSION FOLLOWING THROMBOTIC CARDIOVASCULAR EVENTS IN ELDERLY MEDICARE BENEFICIARIES

    May 1, 2008, 00:00

  • PMH59 HEALTH RELATED QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS- RESULTS AT BASELINE FROM THE COMETA STUDY

    May 1, 2008, 00:00

  • PMH43 MENTAL HEALTH CARE RESOURCE USE BEFORE AND AFTER INITIATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • DB1 REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE

    May 1, 2008, 00:00

  • PHP67 THRESHOLD VALUE FOR A QALY-CORRELATION WITH DISEASE SEVERITY AND DECISION UNCERTAINTY

    May 1, 2008, 00:00

  • PMH46 PREDICTORS OF MEDICATION ADHERENCE AMONG SCHIZOPHRENIA PATIENTS TREATED WITH CONVENTIONAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM

    May 1, 2008, 00:00

  • PHP2 ADHERENCE TO EVIDENCE-BASED GUIDELINES AND MEDICATION COMPLIANCE FOR MULTIPLE CHRONIC DISEASES IN A MANAGED CARE DATABASE

    May 1, 2008, 00:00

  • PRS17 ECONOMIC OUTCOMES IN PATIENTS WITH CYSTIC FIBROSIS- A REVIEW OF THE LITERATURE

    May 1, 2008, 00:00

  • PR3 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

    May 1, 2008, 00:00

  • PDB15 COSTS OF PEN (NOVOPEN(r) 3)VERSUS SYRINGE IN THE TREATMENT OF DIABETES MELLITUSTYPE 2- A PHARMACOECONOMIC STUDY FROM THE SLOVAK REPUBLIC

    May 1, 2008, 00:00

  • PSY46 PSYCHOMETRIC ANALYSIS OFTHE THREE-FACTOR EATING QUESTIONNAIRE- RESULTS FROM A LARGE DIVERSE SAMPLE OF OBESE AND NON-OBESE SUBJECTS

    May 1, 2008, 00:00

  • PMS22 ECONOMIC IMPACT OF ALLOPURINOL HYPERSENSITIVITY SYNDROME

    May 1, 2008, 00:00

  • PDB68 AN ASSESSMENT OF THE IMPACT OF THE COVERAGE GAP UPON MEDICARE PART D BENEFICIARIES UTILIZING INSULIN

    May 1, 2008, 00:00

  • PCV39 INDIRECT COMPARISONS OF RIVAROXABAN VS ALTERNATIVE PROPHYLAXES FORTHE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP ORTOTAL KNEE REPLACEMENT

    May 1, 2008, 00:00

  • PDB1 EXENATIDE UTILIZATION AND EFFECTIVENESS IN A HEALTH PLAN POPULATION

    May 1, 2008, 00:00

  • PIN1 TREATMENT OF HEPATITIS C INFECTION FOR CURRENT OR FORMER SUBSTANCE ABUSERS IN A COMMUNITY SETTING

    May 1, 2008, 00:00

  • PMH24 INITIATING TREATMENT ON GENERIC ANTIDEPRESSANTS MAY NOT SAVE HEALTH CARE COSTS

    May 1, 2008, 00:00

  • PHP23 SPECIALTY BIOLOGIC DRUG COVERAGE UNDER MEDICARE PART D-THE EXPERIENCE OFVULNERABLE BENEFICIARIES WITH RHEUMATOID ARTHRITIS (RA) AND MULTIPLE SCLEROSIS (MS)

    May 1, 2008, 00:00

  • PCN62 LEUPROLIDE ACETATE PERSISTENCE VARIES BY AGE IN PATIENTS WITH PROSTATE CANCER

    May 1, 2008, 00:00

  • PIH10 THE COST-EFFECTIVENESS OF ROUTINE SCREENING FOR VASA PREVIA AT 18-20 WEEKS GESTATION IN ONTARIO

    May 1, 2008, 00:00

  • PMS23 MODELLING OF BURDEN OF FEMORAL NECK FRACTURE IN 2007 FROM PURCHASERS POINT OF VIEW

    May 1, 2008, 00:00

  • PCN50 THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA

    May 1, 2008, 00:00

  • DB2 COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO

    May 1, 2008, 00:00

  • PRS19 SMOKING-CESSATION THERAPY USING VARENICLINE- THE COST-UTILITY OF AN ADDITIONAL 12-WEEK COURSE OF VARENICLINE FOR THE MAINTENANCE OF SMOKING ABSTINENCE

    May 1, 2008, 00:00

  • PSY10 A NOVEL APPROACHTO ADJUST FOR THE IMPACT ON SURVIVAL RESULTING FROM PATIENT CROSS-OVER FROM CONTROLTO EXPERIMENTAL TREATMENT IN CLINICAL TRIALS

    May 1, 2008, 00:00

  • PHC9 THE POTENTIAL SAVINGS IN OPERATING ROOM TIME ASSOCIATED WITH THE USE OF SUGAMMADEXTO REVERSE SELECTED NEUROMUSCULAR BLOCKING AGENTS- FINDINGS FROM A HOSPITAL EFFICIENCY MODEL

    May 1, 2008, 00:00

  • PCV35 GADOFOSVESET IN THE MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN CANADA-A MODEL APPROACH FOCUSING ON DIAGNOSTIC CONFIDENCE

    May 1, 2008, 00:00

  • PMH22 ECONOMIC ASSESSMENT OF THREE COMMONLY USED ANTIPSYCHOTIC AGENTS IN THE PUBLIC SECTOR OF HONG KONG USING A DECISION ANALYTIC MODEL

    May 1, 2008, 00:00

  • PSS19 A PHARMACOECONOMIC EVALUATION OF PEGAPTANIB FOR THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) IN MEXICO

    May 1, 2008, 00:00

  • PCV16 PERMANENT STRESS MAY BE THE TRIGGER OF A HEART ATTACK ON THE FIRST WORK-DAY OF THE WEEK

    May 1, 2008, 00:00

  • PDB69 COMPARISON OF HEALTH CARE UTILIZATION AND COSTS IN TYPE 2 DIABETES PATIENTS INITIATING ANALOG AND HUMAN INSULINS

    May 1, 2008, 00:00

  • PHP3 IS THERE AN ACCEPTABLE LEVEL OF MEDICATION ADHERENCE? A REVIEW OF RETROSPECTIVE ADHERENCE EVALUATION STUDIES

    May 1, 2008, 00:00

  • PUK4 COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN MEXICO

    May 1, 2008, 00:00

  • PCV73 VALIDATION OF AN ABBREVIATED TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM-9) AMONG PATIENTS ON ANTIHYPERTENSIVE MEDICATIONS

    May 1, 2008, 00:00

  • MD5 HEALTH CARE UTILIZATION BY MEDICARE ADVANTAGE BENEFICIARIES IN THE ERA OFTHE MEDICARE PART D DRUG BENEFIT COVERAGE GAP

    May 1, 2008, 00:00

  • PMC18 COMPARISONS OF DATA MINING ALGORITHMS FOR ADVERSE DRUG REACTIONS- AN EMPIRICAL STUDY BASED ONTHE ADVERSE EVENT REPORTING SYSTEM OFTHE FOOD AND DRUG ADMINISTRATION

    May 1, 2008, 00:00

  • PSS46 PROSTAGLANDIN ANALOG USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMAA NETHERLANDS POPULATION BASED ANALYSIS

    May 1, 2008, 00:00

  • PGI16 DISPARITIES IN MEDICATION UTILIZATION AND COMPLIANCE FOR GASTRO-ESOPHAGEAL REFLUX DISEASE- A POPULATION-BASED STUDY

    May 1, 2008, 00:00

  • PND34 ASSOCIATION BETWEEN CHANGE IN OVERALL QUALITY OF LIFE (QOL), DISEASE LEVEL AND FUNCTIONAL STATUS SINCE NATALIZUMAB INITIATION

    May 1, 2008, 00:00

  • PIN48 TRENDS FOR NOSOCOMIAL SOFT TISSUE INFECTIONS, STAPHLOCOCCOUS AUREUS INFECTIONS, AND MRSA IN US HOSPITALS- 1998-2004

    May 1, 2008, 00:00

  • PMC28 RASCH PARTIAL CREDIT ANALYSIS OFTHE SF-12V2 USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2008, 00:00

  • PIH24 AN ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE DUALLY ELIGIBILE MEDICARE AND MEDICAID POPULATION USING THE NEW 2003 BEERS DRUG UPDATE

    May 1, 2008, 00:00

  • PMC9 30 YEARS OF COST-EFFECTIVENESS ANALYSES-A BIBLIOMETRIC REVIEW OF ARTICLES PUBLISHED IN THE ECONOMIC AND MEDICAL LITERATURE- 1976-2005

    May 1, 2008, 00:00

  • PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN) AS COMPARED WITH RANIBIZUMAB (LUCENTIS) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)

    May 1, 2008, 00:00

  • DU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2008, 00:00

  • PSS16 A COST-EFFECTIVENESS ANALYSIS OF TWO TOPICAL OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR THE TREATMENT OF BACTERIAL CONJUNCTIVITIS

    May 1, 2008, 00:00

  • PSS32 QUALITY OF LIFE AND PSYCOLOGICAL DISTRESS IN PATIENT WITH CUTANEUOS LYMPHOMA

    May 1, 2008, 00:00

  • PRS12 INCREMENTAL COST-EFFECTIVENESS OF COMBINATION INHALERTHERAPY IN MODERATE TO SEVERE COPD

    May 1, 2008, 00:00

  • CV4 CANTWO AS RESULT IN A FAILURE?- EFFECT OF ASPIRIN ONTHE RISK OF HEART FAILURE HOSPITALIZATIONS IN CHF PATIENTS ON ACE INHIBITORS

    May 1, 2008, 00:00

  • PCV54 THE COST-UTILITY OF ALISKIREN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. A CANADIAN HEALTH CARE SYSTEM PERSPECTIVE

    May 1, 2008, 00:00

  • PIN8 BUDGET IMPACT OF ADDING DORIPENEMTO A HOSPITAL FORMULARY

    May 1, 2008, 00:00

  • PMH85 PSYCHOTHERAPY AND MEDICATION USE AMONG DEPRESSION PATIENTS

    May 1, 2008, 00:00

  • PCN20 COST ANALYSIS OF IMMUNOGLOBULIN PROPHYLAXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA

    May 1, 2008, 00:00

  • PCV26 BELGIAN BUDGET IMPACT ANALYSES OF ALISKIREN (TEKTURNA/RASILEZ) IN HYPERTENSION

    May 1, 2008, 00:00

  • PSY9 RISK FACTORS AND RISKS ASSOCIATED WITH HOSPITAL STAYS IN PATIENTS WITH MYALGIA

    May 1, 2008, 00:00

  • PHP56 COMPARATIVE ANALYSIS OF THE ACCESS TO PHARMACEUTICALS IN SELECTED EAST EUROPEAN COUNTRIES

    May 1, 2008, 00:00

  • PMH18 RISK OF NEUROLEPTIC MALIGNANT SYNDROME ASSOCIATED WITH ANTIPSYCHOTICS USE IN PATIENTS WITH BIPOLAR DISORDERS RETROSPECTIVE POPULATION-BASED CASE-CONTROL STUDY

    May 1, 2008, 00:00

  • CN3 COMPARISON OFTHE COST-EFFECTIVENESS OF SIX CYCLES OFTAXOTERE, DOXORUBICIN, CYCLOPHOSPHAMIDE (TAC) VERSUS SIX CYCLES OF FLUOROURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE (FAC) INTHE ADJUVANT SETTING OF NODE POSITIVE BREAST CANCERWITH PRIMARY A ...

    May 1, 2008, 00:00

  • PGI24 RACIAL, SOCIAL, AND ECONOMIC DISPARITIES IN KNOWLEDGE AND CARE SEEKING BEHAVIORS FOR GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)

    May 1, 2008, 00:00

  • PMC53 PREVALENCE OF RESEARCH FOCUSED ON GENETICALLY-LINKED DISORDERS- WHERE HAVEWE BEEN AND WHERE AREWE GOING?

    May 1, 2008, 00:00

  • AC5 ORAL ANTIDIABETIC MEDICATION ADHERENCE AND HEALTH CARE COSTSAND UTILIZATION AMONG MEDICAID-ENROLLEDTYPE 2 DIABETES PATIENTS NEWLY STARTING MONOTHERAPY

    May 1, 2008, 00:00

  • PSY48 IMPACT OF IMMUNETHROMBOCYTOPENIC PURPURA ON HEALTH CARE RESOURCE USE ANDWORKPLACE PRODUCTIVITY

    May 1, 2008, 00:00

  • PND17 SEVERITY OF ILLNESS AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS- AN ANALYSIS OF COST QUINTILES

    May 1, 2008, 00:00

  • PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS

    May 1, 2008, 00:00

  • The Impact of Chronic Hepatitis B on Quality of Life- A Multinational Study of Utilities from Infected and Uninfected Persons

    May 1, 2008, 00:00

  • PIH22 CARESS- THE CANADIAN REGISTRY OF SYNAGIS()

    May 1, 2008, 00:00

  • PRS39 THE IMPACT OF FORMULARY POLICIES ON THE USE OF MEDICATION FOR RESPIRATORY DISEASE- A COMPARISON OF DRUG UTILIZATION IN THE PROVINCES OF ONTARIO AND ALBERTA

    May 1, 2008, 00:00

  • PSS14 COST-EFFECTIVENESS OF THE TREATMENT FOR MODERATE TO SEVERE PSORIASIS IN MEXICO- INFLIXIMAB, ETANERCEPT AND EFALIZUMAB

    May 1, 2008, 00:00

  • PCV30 CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT

    May 1, 2008, 00:00

  • PCN79 METHODS FOR ASSESSING QUALITY OF LIFE IN CANCER PATIENTS EXPERIENCING COMPLICATIONS- OSTEONECROSIS OF THE JAW PILOT STUDY

    May 1, 2008, 00:00

  • Uncertainty in Decision-Making- Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People

    May 1, 2008, 00:00

  • PND14 ECONOMIC EVALUATION OF SATIVEX FOR TREATMENT OF NEUROPATHIC PAIN IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE

    May 1, 2008, 00:00

  • PMC40 PHARMACY STUDENTS PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE FOR MULTIPLE CHRONIC HEALTH STATES MEASURED VIA ALTERNATIVE METHODS FOR UTILITY ASSESSMENT

    May 1, 2008, 00:00

  • PGI4 A BRAZILIAN CROSS SECTIONAL STUDY TO EVALUATE HOSPITALIZATION AMONG MODERATE AND SEVERE CROHNS DISEASE PATIENTS

    May 1, 2008, 00:00

  • PRS22 EFFECT OF PATIENTS OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH OMALIZUMAB (XOLAIR) THERAPY FOR ALLERGIC ASTHMA

    May 1, 2008, 00:00

  • PIN3 DATA MINING PHYSICIAN DECISION AND INVESTIGATING TREATMENT OPTIONS OF OSTEOMYELITIS

    May 1, 2008, 00:00

  • PCN70 THE IMPACT OF HODGKIN S LYMPHOMA ON HEALTH RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PMC51 MEDICATION ADHERENCE- A CONCEPTUAL REVIEW

    May 1, 2008, 00:00

  • PRS16 INCREMENTAL DIRECT MEDICAL EXPENDITURES ASSOCIATED WITH ADULT ASTHMA IN THE UNITED STATES

    May 1, 2008, 00:00

  • PSY21 THE COST-EFFECTIVENESS OF LYRICA (PREGABALIN) IN PATIENTS WITH CENTRAL NEUROPATHIC PAIN

    May 1, 2008, 00:00

  • PDB37 FACTORS ASSOCIATED WITH HEALTH CARE COSTS AMONG ELDERLY PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PIN37 AN EXAMINATION OF THE CORRELATION BETWEEN QUALITY OF PATIENT CARE AND PATIENT RACE OR SOCIAL CLASS IN INPATIENT APPENDICITIS CASES

    May 1, 2008, 00:00

  • PHP42 PHYSICIANS VIEWS REGARDING PRESCRIPTION DRUG ACCESS UNDER MEDICARE PART D

    May 1, 2008, 00:00

  • PDB7 EVALUATION OF INSULIN CONTAINING ANTI-DIABETIC REGIMENS IN HIGH-RISK CARDIOVASCULAR PATIENTS WITH A PRE-TREATMENT AIC MEASUREMENT GREATER THAN 9

    May 1, 2008, 00:00

  • PSS4 THE RCT EVIDENCE OF COMPARATIVE EFFECTIVENESS AND SAFETY OF TOPICAL GLAUCOMA MEDICATION

    May 1, 2008, 00:00

  • PCN8 IMPROVED SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME BYTEMOZOLOMIDE AS ADJUVANT THERAPY- A RETROSPECTIVE COHORT STUDY

    May 1, 2008, 00:00

  • PRS6 A COST-EFFECTIVENESS MODEL FOR SMOKING CESSATION THERAPY USING VARENICLINE

    May 1, 2008, 00:00

  • PSS38 PATIENTS PERCEPTION OF LIFE FREE OF GLASSES AFTER CATARACT SURGERY- DEVELOPMENT OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)

    May 1, 2008, 00:00

  • PMH33 COST-EFFECTIVENESS OF ARIPIPRAZOLE FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PSS30 USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS- RESULTS FROM A PHASE III STUDY

    May 1, 2008, 00:00

  • PND44 CANADIAN PATIENT SURVEY TO ASSESS PATIENTS PLIGHT TO DYSTONIA DIAGNOSES AND BOTULINUM TOXIN TYPE A TREATMENT

    May 1, 2008, 00:00

  • PMS27 DOES THE FUNDING SOURCE INFLUENCE THE RESULTS IN ECONOMIC EVALUATIONS? A CASE- STUDY IN BISPHOSPHONATES FORTHETREATMENT OF OSTEOPOROSIS

    May 1, 2008, 00:00

  • PMH10 TREATMENT PATTERNS PRIORTO INITIATING DEPOT TYPICAL ANTIPSYCHOTICS FOR NON-ADHERENT SCHIZOPHRENIA PATIENTS

    May 1, 2008, 00:00

  • PIH15 STUDENT PHARMACIST INTERVENTIONS LEAD TO COST MINIMIZATION OF MEDICARE PART D PRESCRIPTION DRUG PLAN COSTS

    May 1, 2008, 00:00

  • PGI9 DEVELOPMENT OF A CLAIMS-BASED MARKOV MODEL FOR CROHNS DISEASE

    May 1, 2008, 00:00

  • PMH58 IMPROVEMENT IN PERSONAL AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS TREATED WITH RISPERIDONE LONG ACTING INJECTION)- 6-MONTH RESULTS FROM E-STAR

    May 1, 2008, 00:00

  • PCV20 UPDATING THE RXRISK-V- CREATING A CROSSWALK BETWEEN VA AND FIRSTDATABANK THERAPEUTIC CATEGORIES

    May 1, 2008, 00:00

  • CASE 5 THE CENTER FOR DRUG POLICY- PARTNERS HEALTHCARE

    May 1, 2008, 00:00

  • PCN38 THE IMPACT OF BREAST CANCER CARE DEVELOPMENT ON MEDICAL AND ECONOMICAL OUTCOMES IN ATOTAL SOCIETAL COST CONTEXT

    May 1, 2008, 00:00

  • PND41 PHYSICIAN AND PATIENT REPORTED OUTCOMES REVEAL RAPID ONSET OF IMPROVEMENT AND OVERALL CONVENIENCE, TOLERABILITY AND EASE-OF-USE WITH RASAGILINE IN PARKINSONS DISEASE (PD) IN LEGATO

    May 1, 2008, 00:00

  • PIN15 ECONOMIC EVALUATION OFTIPRANAVIR IN THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

    May 1, 2008, 00:00

  • PND38 EVALUATION OF INTERVIEWER TRAINING FOR AN INTERVIEWER ADMINISTERED PATIENT-REPORTED OUTCOME IN A GLOBAL CLINICAL TRIAL

    May 1, 2008, 00:00

  • PMC5 AN ANATOMY OF PHARMACEUTICAL COST-UTILITY ANALYSES, 1976-2005

    May 1, 2008, 00:00

  • PMC32 PREDICTING SF-6D PREFERENCE-BASED UTILITIES USING MEAN SF-36 HEALTH DIMENSION SCORESWHEN PATIENT LEVEL DATA ARE NOT AVAILABLE

    May 1, 2008, 00:00

  • Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept- Continuous versus Interrupted Treatment

    May 1, 2008, 00:00

  • PMS37 ASSESSING THE VALIDITY AND RELIABILITY OF A SIMPLE ACTIVITY PARTICIPATION MEASURE FOR RHEUMATOID ARTHRITIS CLINICAL TRIALS

    May 1, 2008, 00:00

  • PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY

    May 1, 2008, 00:00

  • PCV99 THE FIRST MOVER STRIKES AGAIN. COST-EFFECTIVENESS OF STATINS AND PRESCRIBING BEHAVIOR IN PORTUGAL

    May 1, 2008, 00:00

  • PND15 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PCV13 ANGINA FOLLOWING REVASCULARIZATION-FREQUENCY, PATIENT CHARACTERISTICS AND TIMING

    May 1, 2008, 00:00

  • PIN34 HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH CHRONIC HEPATITIS C IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PHP54 PREVALENCE OF CONDITIONS IN THE US EMPLOYER-INSURED POPULATION

    May 1, 2008, 00:00

  • PRS30 USE OF INTERACTIVE VOICE RESPONSE (IVR)TO COLLECT DAILY PATIENT DIARY DATA IN A CLINICAL TRIAL OF SEASONAL RHINITIS

    May 1, 2008, 00:00

  • PMC17 A METHOD FOR CONVERTING NATIONAL DRUG CODES (NDCS) TO GENERIC ANDTHERAPEUTIC CATEGORY CODES FOR USE IN LARGE DATABASE STUDIES OF PRESCRIPTION DRUG CLAIMS

    May 1, 2008, 00:00

  • PMH4 ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIAS BAYESIAN META-ANALYSIS OF DIRECT AND INDIRECT COMPARISONS

    May 1, 2008, 00:00

  • PMH47 THE RELATIONSHIP BETWEENTHE ANTIPSYCHOTIC MEDICATION ADHERENCE AND PATIENT OUTCOMES AMONG BIPOLAR DISORDER PATIENTS

    May 1, 2008, 00:00

  • PIH25 VARIATIONS IN ANTIPSYCHOTIC THERAPY AND SHORT-TERM MORTALITY ACROSS LONG-TERM CARE HOMES

    May 1, 2008, 00:00

  • PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA

    May 1, 2008, 00:00

  • PCN88 FACTORS ASSOCIATED WITH THE PRESCRIPTION OF ADJUVANT HORMONAL THERAPIES AMONG MEDICAID ENROLLEESWITH BREAST CANCER

    May 1, 2008, 00:00

  • PDB61 PREDICTORS OF INSULIN DELIVERY SYSTEM USE IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PMS9 COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) ORTUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS)-A CANADIAN PERSPECTIVE

    May 1, 2008, 00:00

  • PCV18 FACTORS ASSOCIATED WITH RISK OF METABOLIC SYNDROME FOR US FIRST GENERATION ADOLESCENTS (AGES 12-17)

    May 1, 2008, 00:00

  • PMS6 BUDGET IMPACT ANALYSIS OFABATACEPT INCLUSION FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE BRAZILIAN PUBLIC SYSTEM

    May 1, 2008, 00:00

  • MH2 ECONOMIC AND CLINICAL CONSEQUENCES ASSOCIATED WITH POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTIPSYCHOTICS AND CONCOMITANT MEDICATIONS IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PCASE6 HOW SHOULD NEWTECHNOLOGIES AND NEW DEVICES BE ASSESSED IN A HOSPITAL SYSTEM?

    May 1, 2008, 00:00

  • PMH27 COST-EFFECTIVENESS OF A MINIMAL INTERVENTION STRATEGY FOR STRESS-RELATED SICK LEAVE IN GENERAL PRACTICE- RESULTS OF AN ECONOMIC EVALUATION ALONGSIDE A PRAGMATIC RANDOMIZED CONTROLLED TRIAL

    May 1, 2008, 00:00

  • PIN44 ANTIBIOTIC PRESCRIBING IN THE HOSPITAL EMERGENCY DEPARTMENT

    May 1, 2008, 00:00

  • PCV14 EVALUATION OF RESISTANT HYPERTENSION IN A USUAL-CARE SETTING

    May 1, 2008, 00:00

  • PMH15 ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PHP79 PHYSICIAN QUALITY MEASUREMENT IN THE HEALTH PLAN PPO SETTING-THE IMPORTANCE OF SCORING ALGORITHMS

    May 1, 2008, 00:00

  • PND20 ECONOMIC CONSEQUENCES OF MULTIPLE SCLEROSIS- A POPULATION-BASED STUDY

    May 1, 2008, 00:00

  • PHP60 DEVELOPMENT OF A DRUG INVENTORY MANAGEMENT MODEL FOR THE STATE HOUSE MEDICAL CENTRE, ABUJA, NIGERIA

    May 1, 2008, 00:00

  • PIN13 ECONOMIC EVALUATION OF POSACONAZOLE VS. STANDARD AZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH PROLONGED NEUTROPENIA IN CANADA

    May 1, 2008, 00:00

  • PMS11 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB FOR RHEUMATOID ARTHRITIS IN TAIWAN

    May 1, 2008, 00:00

  • PDB75 PRESCRIBING PATTERN AND PREDICTORS ASSOCIATED WITH THE USE OF HYPOGLYCAEMIC DRUGS- A CROSS-SECTIONAL STUDY IN ITALIAN GENERAL PRACTICE

    May 1, 2008, 00:00

  • PRS9 THE COST-EFFECTIVENESS OF TARGETED PRESCRIBING OF ANTIMICROBIALS IN CANADA FOR COMMUNITY-ACQUIRED PNEUMONIA IN AN ERA OF ANTIMICROBIAL RESISTANCE

    May 1, 2008, 00:00

  • PMS42 A COMPARISON OF PROVINCIAL PRESCRIPTION-ONLY PHARMACEUTICAL DATABASE WITH SELF-REPORTED USAGE OF ACETAMINOPHEN AND NSAIDS ACCORDING TO OSTEOARTHRITIS STAGE IN BRITISH COLUMBIA

    May 1, 2008, 00:00

  • PGI2 HOSPITALIZATIONS FOR GASTROINTESTINAL EVENTS AMONG USERS OF COX 2 INHIBITORS COMPARED WITH TRADITIONAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS WITH PROTON-PUMP INHIBITORS

    May 1, 2008, 00:00

  • PMC11 ACCOUNTING FOR THE PLACEBO RESPONSE IN COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PCV75 LOW-DENSITY LIPOPROTEIN APHERESIS FORTHE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA

    May 1, 2008, 00:00

  • PRS20 A LONG TERM COST-EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN KOREA

    May 1, 2008, 00:00

  • PDB52 SYSTEMATIC REVIEW OF ADHERENCE, COMPLIANCE AND QUALITY OF LIFE IN TYPE 2 DIABETES PATIENTS

    May 1, 2008, 00:00

  • PSS8 ESTIMATING COST-EFFECTIVENESS OF TOPICAL OCULAR HYPOTENSIVES FOR MAINTAINING PERSISTENT THERAPY USING AREA UNDERTHE SURVIVAL CURVE

    May 1, 2008, 00:00

  • PMC44 IS A LITERAL BACKTRANSLATION IN PRO DOCUMENTS ALWAYS THE BEST OPTION?

    May 1, 2008, 00:00

  • IN2 UPPER RESPIRATORY ILLNESS AND EMPLOYEE PRODUCTIVITY-RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF)

    May 1, 2008, 00:00

  • PCN28 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB-CHOP VS. CHOP ON NON-HODGKIN LYMPHOMA PATIENTS IN THE MEXICAN CONTEXT

    May 1, 2008, 00:00

  • PRS28 ADHERENCE TO INHALED CORTICOSTEROID USE AND LOCAL ADVERSE EVENTS IN PERSISTENT ASTHMA

    May 1, 2008, 00:00

  • PCV77 ASSESSMENT OF CONTROL AND TREATMENT PATTERNS IN AN ELDERLY POPULATION WITH COMORBID DIABETES AND HYPERTENSION

    May 1, 2008, 00:00

  • PMC31 CONTROLLING MEASUREMENT ERROR OF PATIENT-REPORTED-OUTCOMES DURING THE IMPLEMENTATION STAGE OF CLINICAL TRIALS

    May 1, 2008, 00:00

  • PCASE2 THE ROLE OF ECONOMIC EVALUATION IN CHANGING DECISION-MAKER BEHAVIOURS -A CASE STUDY FROM TRINIDAD AND TOBAGO

    May 1, 2008, 00:00

  • PMH8 TREATMENT DURATION FOLLOWING INITIATION ON ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIA PATIENTS WITH VERSUS WITHOUT A METABOLIC SYNDROME

    May 1, 2008, 00:00

  • PSS37 MAPPING THE DERMATOLOGY QUALITY OF LIFE INDEX (DLQI)TO HEALTH-RELATED UTILITYVIATHE SF-12 IN SUBJECTS WITH ECZEMA

    May 1, 2008, 00:00

  • PUK19 COMPARISON OF THE HEALTH-RELATED QUALITY OF LIFE BETWEEN PATIENTS UNDERGOING PERITONEAL DIALYSIS AND HAEMODIALYSIS

    May 1, 2008, 00:00

  • PIN11 COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES

    May 1, 2008, 00:00

  • PMS3 EFFICACY OF COX-2 SELECTIVE NSAIDS, NON-SELECTIVE NSAIDS, AND ACETAMINOPHEN IN OSTEOARTHRITIS- A BAYESIAN MIXED TREATMENT COMPARISON

    May 1, 2008, 00:00

  • PHP35 CHARACTERIZING PHARMACY AND MEDICAL CLAIMS FOR A PRIVATE INSURANCE POLYPHARMACY POPULATION

    May 1, 2008, 00:00

  • PMC29 INTERNATIONAL VALUATION SET FOR EQ-5D HEALTH STATES

    May 1, 2008, 00:00

  • PUK8 A REVIEW- DIFFERING COSTS AND EFFECTS IN ECONOMIC EVALUATIONS OF TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

    May 1, 2008, 00:00

  • PND24 IMPACT OF NON-ADHERENCE TO ANTIEPILEPTIC DRUGS ON MORBIDITY

    May 1, 2008, 00:00

  • PCN48 LONGITUDINAL COMPARISON ACROSS TREATMENTS, RISK AND AGE OF WORK LOSS COSTS IN PROSTATE CANCER PATIENTS- 10 YEAR PATTERNS

    May 1, 2008, 00:00

  • PGI11 DIRECT COST SIMILARITIES BY POINT OF SERVICE FOR PERSONS WITH CONSTIPATION OR IRRITABLE BOWEL SYNDROME PLUS CONSTIPATION IN THE SIX MONTHS BEFORE AND AFTER DIAGNOSIS- AN EMPLOYER PERSPECTIVE

    May 1, 2008, 00:00

  • AC7 COMPARING ADHERENCE TO FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PRS3 AVALIDATION STUDY ON USING MORTALITY RISK STRATIFICATION TOOL TO STRATIFY ECONOMIC RISK IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD)

    May 1, 2008, 00:00

  • PHP16 IMPROVING HEALTH TECHNOLOGY APPRAISAL AND DECISION-MAKING- WHAT HAS THE BRITISH PARLIAMENTS INQUIRY OF NICE TAUGHT US?

    May 1, 2008, 00:00

  • PCN91 A PREVALENCE-BASED ECONOMIC ANALYSIS OF THE GROWTH IN CANCER TREATMENT SPENDING IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCN73 COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FORACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD- DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MONSTER (BFM)

    May 1, 2008, 00:00

  • PIN33 A DYNAMIC MODEL FOR ASSESSING THE IMPACT OF EMERGING VACCINE TECHNOLOGIES ON MEASLES DISEASE BURDEN IN DEVELOPING COUNTRIES

    May 1, 2008, 00:00

  • PMH7 CLINICAL AND FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION- INTERIM RESULTS FROM OBSERVATIONAL STUDIES CONDUCTED IN AUSTRALIA, BELGIUM AND THE UNITED STATES

    May 1, 2008, 00:00

  • PCN26 COST-EFFECTIVENESS MODELING OF COLORECTAL CANCER I0YEARS SCREENING USING COMPUTEDTOMOGRAPHIC COLONOGRAPHYVERSUS COLONOSCOPY AND FECAL OCCULT BLOOD TESTS

    May 1, 2008, 00:00

  • MD1 MEDICARE PART D- EARLY EVIDENCE ON PRESCRIPTION DRUGTREATMENT PATTERNS, HOSPITALIZATION OFFSETS AND MEDICARE SPENDING

    May 1, 2008, 00:00

  • PRS26 PREFERENCES FOR ONSET OF EFFECT OF COMBINATION MAINTENANCE MEDICATION AMONG ASTHMA PATIENTS

    May 1, 2008, 00:00

  • IN3 A MICROSIMULATION OF THE COST-EFFECTIVENESS OF MARAVIROC FORANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS

    May 1, 2008, 00:00

  • PMS18 COST-EFFECTIVENESS OFABATACEPT IN PATIENTS WITH MODERATELYTO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN BRAZIL

    May 1, 2008, 00:00

  • PND7 BUDGET IMPACT OFTRANSDERMAL ADHESIVES OF RIVASTIGMINE IN BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2008, 00:00

  • PMC34 INTERNATIONAL SURVEY ONWTP FOR ONE ADDITIONAL QALY GAIN-HOW MUCH IS THE THRESHOLD OF COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PIH1 PREVENTION OF FALLS AND FALL-RELATED INJURIES IN THE COMMUNITY-DWELLING ELDERLYA REVIEW

    May 1, 2008, 00:00

  • PIN24 COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN NON-NEUTROPENIC PATIENTS IN MEXICO

    May 1, 2008, 00:00

  • PCV15 SEASONAL VARIATION OF HEART ATTACKS IN WOMEN

    May 1, 2008, 00:00

  • PMH84 PREDICTORS OFTREATMENT INITIATION OF DULOXETINE VS. VENLAFAXINE XR FOR PATIENTS WITH MAJOR DEPRESSION DISORDER IN MANAGED CARE SETTINGS

    May 1, 2008, 00:00

  • PSS31 ASSESSMENT OF QUALITY OF LIFE IN DAILY CLINICAL DERMATOLOGICAL ROUTINE- QUESTIONNAIRES AND CHECKLIST

    May 1, 2008, 00:00

  • WH2 DISABILITY AND ASSOCIATED COSTS AMONGWOMEN WITH EMPLOYER-SPONSORED INSURANCE AND NEWLY DIAGNOSED BREAST CANCER

    May 1, 2008, 00:00

  • PUK13 A COST MINIMIZATION ANALYSIS OF EPOETIN ZETA FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE

    May 1, 2008, 00:00

  • PCV60 USING A LONGITUDINAL MODEL TO ANALYZE DRUG COMPLIANCE

    May 1, 2008, 00:00

  • PCN81 INJECTABLE CHEMOTHERAPYVS CAPECITABINE- PREFERENCE IN BRAZILIAN PATIENTS

    May 1, 2008, 00:00

  • PSY27 BURDEN OF OBESITY- 10-YEAR REVIEW OF PUBLISHED LITERATURE ON DIRECT AND INDIRECT COSTS IN NINE COUNTRIES

    May 1, 2008, 00:00

  • PMC14 EXPLORING CANDIDATE DIFFERENCES BETWEEN DRUG COHORTS PRIOR TO EXPOSURE- A SYSTEMATIC APPROACH USING MULTIPLE OBSERVATIONAL DATABASES

    May 1, 2008, 00:00

  • PMC7 TOTAL DIRECT MEDICAL EXPENDITURE OF CHRONIC DISEASES UNDER DIFFERENT ECONOMETRIC MODELS

    May 1, 2008, 00:00

  • PHP75 SATISFACTION WITH MEDICATION- PRELIMINARY RESULTS FROM A NOVEL PATIENT REGISTRYTRACKING SATISFACTION WITH DIFFERENT CHRONIC MEDICATIONS

    May 1, 2008, 00:00

  • PMH56 THE IMPACT OF DULOXETINE, VENLAFAXINE AND ESCITALOPRAM USE AND PRESCRIPTION COPAYS ON MEDICATION PERSISTENCE, HEDIS MEASURES AND EXPENDITURES

    May 1, 2008, 00:00

  • PRS29 PATIENT, CAREGIVER, AND PHYSICIAN PERCEPTIONS OF MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE- FINDINGS FROM QUALITATIVE RESEARCH

    May 1, 2008, 00:00

  • PSY49 THE WILLINGNESS TO PAY TO MINIMIZE CHRONIC PAIN

    May 1, 2008, 00:00

  • PND4 TRENDS AMONG HOSPITALIZED CYSTIC FIBROSIS PATIENTS

    May 1, 2008, 00:00

  • PCN16 COST DIVERSITY OF DRG BASED COLORECTAL CANCER THERAPIES IN HUNGARY

    May 1, 2008, 00:00

  • CV2 THE COST-EFFECTIVENESS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE (HF)-AN ASSESSMENT OF THE LOW LEFT VENTRICULAR EJECTION FRACTION (LOW-LVEF) TRIALS IN THE CANDESARTAN-IN-HEART-FAILURE-ASSESSMENT-OF-REDUCTION-IN-MORTALITYA ...

    May 1, 2008, 00:00

  • PSS7 THE COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO PDT-VAND BSC FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CANADA

    May 1, 2008, 00:00

  • PMS17 LONGITUDINAL ESTIMATES AND COST-EFFECTIVENESS ANALYSIS OF ANTI-RESORPTIVE AGENTS FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRACTURES BASED ON US NATIONAL SURVEYS

    May 1, 2008, 00:00

  • PDB67 DESCRIPTIVE ANALYSIS OF BODY WEIGHT AND CLINICAL EFFECTIVENESS MEASURES ASSOCIATED WITH TYPE 2 DIABETES THERAPIES IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE

    May 1, 2008, 00:00

  • PCV61 IMPACT OF PRESCRIPTION COPAY ON ADHERENCE WITH RENIN-ANGIOTENSIN SYSTEM AGENTS IN HEART FAILURE PATIENTS

    May 1, 2008, 00:00

  • PHP71 PHARMACY STUDENTS ABILITYTO RECOGNIZE DRUG-DRUG INTERACTIONS (DDIS)

    May 1, 2008, 00:00

  • PMC16 CREATING NATIONAL WEIGHTS FOR A LARGE-SCALE, PATIENT LONGITUDINAL DATABASE

    May 1, 2008, 00:00

  • PCN23 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT

    May 1, 2008, 00:00

  • DU3 CALIFORNIA WILDFIRES ANDTHEIR IMPACT ON MEDICATION ACQUISITION

    May 1, 2008, 00:00

  • PCN45 RESOURCE UTILIZATION AND COST ESTIMATION OF ADVERSE EVENTS OF NON-SMALL CELL LUNG CANCER TREATMENT IN MEXICAN PATIENTS. RESULTS OF A DELPHI PANEL

    May 1, 2008, 00:00

  • DU4 PRESCRIPTION DRUG UTILIZATION AMONG A NATIONALLY REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES WITH HEART FAILURE

    May 1, 2008, 00:00

  • PMH70 AN INVESTIGATION OF EVIDENCE-BASED USE OF ATYPICAL ANTIPSYCHOTICS IN ARKANSAS MEDICAID PEDIATRIC

    May 1, 2008, 00:00

  • PSY28 A SYSTEMATIC REVIEW OF LOW BACK PAIN COST OF ILLNESS STUDIES IN THE UNITED STATES AND INTERNATIONALLY

    May 1, 2008, 00:00

  • PCV2 STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDINGTO NATIONAL LIPID TREATMENT GUIDELINES

    May 1, 2008, 00:00

  • PSY30 EVALUATION OF COST AND OUTCOMES OF WEIGHT CONTROL PROGRAM IN A REGIONAL HOSPITAL AT SOUTHERNTAIWAN

    May 1, 2008, 00:00

  • PND21 COST-UTILITY OF PRAMIPEXOL COMPARED WITH L-DOPA/CARBIDOPA INTHE TREATMENT OF PARKINSONS DISEASE IN MEXICO

    May 1, 2008, 00:00

  • PGI26 FINANCIAL IMPACT OF LIFTING A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR CHRONIC CONSTIPATION PATIENTS IN A COMMERCIAL MANAGED CARE POPULATION (AGE 65 YEARS)

    May 1, 2008, 00:00

  • PCN11 A BUDGET IMPACT ANALYSIS OF IXABEPILONE IN TREATING METASTATIC CANCER PATIENTS

    May 1, 2008, 00:00

  • PCV89 PRE AND POST STROKE STATIN USE AND ASSOCIATED HEALTH CARE COSTS AMONG ELDERLY STROKE SURVIVORS

    May 1, 2008, 00:00

  • PDB13 PREDICTING INPATIENT HOSPITALIZATION RISKS FOR MEDICAID DIABETES PATIENTS

    May 1, 2008, 00:00

  • PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE- POPULATION-BASED NATURAL EXPERIMENT

    May 1, 2008, 00:00

  • PMH2 BENCHMARKING SCHIZOPHRENIA WITH A FOCUS ON PHARMACOTHERAPYAND METABOLIC SYNDROME

    May 1, 2008, 00:00

  • PCN22 IS CAPECITABINE A COST-EFFECTIVE ADJUVANT TREATMENT OF STAGE III COLON CANCER IN ONTARIO?

    May 1, 2008, 00:00

  • PDB8 DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON OUTCOMES IN THE HOSPITAL SETTING

    May 1, 2008, 00:00

  • PIN18 THE IMPACT OF PEDIATRIC ADVERSE EVENTS ON THE COST-EFFECTIVENESS OF OSELTAMIVIR

    May 1, 2008, 00:00

  • PMS13 COST EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PMH34 TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- ESTIMATING THE MAXIMUM ALLOWABLE COST OF PSYCHOSOCIAL INTERVENTIONS IN THE UNITED STATES, GERMANY. THE NETHERLANDS, SWEDEN, AND THE UNITED KINGDOM

    May 1, 2008, 00:00

  • PCV50 UP-TITRATION OF STATIN THERAPY TO MEET CANADIAN TARGET LIPID GOALS- ECONOMIC IMPACT OFTITRATION ASSOCIATED WITH COMPARATIVE EFFICACY OF ROSUVASTATIN, ATORVASTATIN, SIMVASTATIN AND PRAVASTATIN

    May 1, 2008, 00:00

  • PCV47 MEDICARE OUTLIER PAYMENTS FOR CORONARY ARTERY BYPASS GRAFTING

    May 1, 2008, 00:00

  • PMH11 ASSESSING THE REPORTING AND SCIENTIFIC QUALITY OF META-ANALYTIC RESEARCH SYNTHESISING RANDOMIZED CONTROLLED TRIALS FOR ANXIETY DISORDER TREATMENTS

    May 1, 2008, 00:00

  • PSS1 CO-MORBIDITIES INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS

    May 1, 2008, 00:00

  • PUK3 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION THAT MAY REQUIRE DRUG DOSAGE ADJUSTMENT

    May 1, 2008, 00:00

  • Time and Expected Value of Sample Information Wait for No Patient

    May 1, 2008, 00:00

  • PUK10 ECONOMIC EVALUATION OF POLYCLONAL ANTIBODIES FOR THE MANAGEMENT OF HIGH RISK PATIENTS WITH ACUTE REJECTION IN RENAL TRANSPLANTATION AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2008, 00:00

  • PMC13 USE OF POTENTIALLY INAPPROPRIATE PSYCHOACTIVE MEDICATIONS AND FALLS IN U.S. NURSING HOME RESIDENTS

    May 1, 2008, 00:00

  • Cost-Utility Analysis of Rimonabant in the Treatment of Obesity

    May 1, 2008, 00:00

  • PGI20 PARTIAL RESPONDERS TO PPI TREATMENT; HOW DO THEY DIFFER FROM OTHER GERD PATIENTS IN TERMS OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILISATION?-A DATABASE ANALYSIS

    May 1, 2008, 00:00

  • OM1 VALIDATING A SURVEY INSTRUMENT USING NONPARAMETRIC ITEM RESPONSETHEORY- APPLICATION OF KERNEL REGRESSION

    May 1, 2008, 00:00

  • PMS10 THE COST-EFFECTIVENESS OF ABATACEPT VERSUS RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PERSPECTIVE OF THE CANADIAN PUBLICLY FUNDED HEALTH CARE SYSTEM

    May 1, 2008, 00:00

  • PSY14 ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTSWHO HAVE RECEIVED ONE PRIOR THERAPY

    May 1, 2008, 00:00

  • PMS46 TREATMENTS FOR UPPER-LIMB POST-STROKE SPASTICITY- A CRITICAL EVALUATION

    May 1, 2008, 00:00

  • PMH17 METABOLIC MONITORING AMONG SCHIZOPHRENIA PATIENTS INITIATED ON ATYPICAL ANTIPSYCHOTICS IN THE VETERAN HEALTH ADMINISTRATION

    May 1, 2008, 00:00

  • PMS43 CHARACTERISTICS OF PHARMACEUTICS HAVING NO ALTERNATIVES

    May 1, 2008, 00:00

  • PDB38 PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • PCN53 THE BURDEN OF MANAGING PLEURAL EFFUSIONS IN CML PATIENTS POST-IMATINIB FAILURE-A LITERATURE-BASED ECONOMIC ANALYSIS

    May 1, 2008, 00:00

  • PCN63 RACIAL DIFFERENCES IN MEDICATION ADHERENCE TO ADJUVANT HORMONAL THERAPY IN MEDICAID ENROLLED WOMEN WITH PRIMARY BREAST CANCER- A COMPARISON USING TWO ESTIMATION METHODOLOGIES

    May 1, 2008, 00:00

  • PDB56 PREFERENCES FOR ORAL ANTIDIABETIC AGENTS AMONG PEOPLE WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PMC36 THE USE OF A MOBILE PHONE FOR ASSESSING MOOD AND PERFORMANCE IN EVERYDAY LIFE

    May 1, 2008, 00:00

  • PHP78 STABILITY OF PHYSICIAN PERFORMANCE ON PAY-FOR-PERFORMANCE PROCESS MEASURES OVERTIME- EFFECT OF PATIENT DENOMINATOR THRESHOLDS

    May 1, 2008, 00:00

  • PGI17 ADHERENCE TO INFLIXIMAB MAINTENANCE THERAPY AND ITS IMPACT ON HOSPITALIZATION OF PATIENTS WITH CROHNS DISEASE

    May 1, 2008, 00:00

  • PCN95 CHANGE IN THE USE OF BREAST CONSERVING SURGERY BEFORE AND AFTER GUIDELINE PUBLICATION IN JAPAN

    May 1, 2008, 00:00

  • PCV96 THE EFFECT OF MEASUREMENT ERROR FROM POINT-OF-CARE INR DEVICES ON WARFARIN DOSING DECISIONS

    May 1, 2008, 00:00

  • PM1 RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2008, 00:00

  • PDB49 INFLUENCE OF FAMILY STRUCTURE ON EMERGENCY ROOM UTILIZATION OF DIABETIC MOTHERS

    May 1, 2008, 00:00

  • PSY54 DEVELOPMENT OF AN OPIOID ROTATION MODEL

    May 1, 2008, 00:00

  • PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO

    May 1, 2008, 00:00

  • PHP31 DRUG PROXIES FOR IDENTIFYING SPECIFIC DIAGNOSES IN MEDICARE PART D

    May 1, 2008, 00:00

  • PMH14 DIFFERENTIAL EFFECTS OF OLANZAPINE AND CLOZAPINE ON TYPE II DIABETES- FINDINGS FROM A CLAIMS DATABASE

    May 1, 2008, 00:00

  • PCN93 THREE SCIENTIFIC PARADIGMS IN HEALTH TECHNOLOGY ASSESSMENT- EXPERIENCES OF THE COMMITTEE TO EVALUATE DRUGS IN ONTARIO, CANADA

    May 1, 2008, 00:00

  • PGI18 LINGUISTIC VALIDATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) IN 35 LANGUAGES

    May 1, 2008, 00:00

  • PCV88 OLD HABITS DIE HARD- A NATIONWIDE UTILIZATION STUDY OF CALCIUM CHANNEL BLOCKERS IN TAIWAN

    May 1, 2008, 00:00

  • PMS44 PRESCRIPTION TREATMENT PATTERNS IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN

    May 1, 2008, 00:00

  • PIH3 HOSPITALIZATIONS AND MORTALITY ASSOCIATED WITH INCIDENT POTENTIALLY INAPPROPRIATE MEDICATIONS USE AMONG ELDERLY INDIANA MEDICAID BENEFICIARIES RESIDING IN NURSING HOMES

    May 1, 2008, 00:00

  • PIH27 GENERIC SUBSTITUTION OF WARFARIN AMONG THE ELDERLY- AN EXAMINATION OF HOSPITAL AND EMERGENCY ROOM USE

    May 1, 2008, 00:00

  • PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN

    May 1, 2008, 00:00

  • PMH83 USING RETAIL PHARMACY PRESCRIPTION DATATO INVESTIGATE THE SEASONALITY OF ADHDTREATMENT- JANUARY 2003-OCTOBER 2007

    May 1, 2008, 00:00

  • PMS29 BAYESIAN COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ANKYLOSING SPONDYLITIS

    May 1, 2008, 00:00

  • PSS21 COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY

    May 1, 2008, 00:00

  • PCV104 RELATIONSHIP BETWEEN QUALITY OF CARE AND EXCESSIVE COST FOR MEDICARE PATIENTS UNDERGOING LOWER EXTREMITY BYPASS SURGERY

    May 1, 2008, 00:00

  • DB4 RETROSPECTIVE STUDY OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY METFORMIN MONOTHERAPY

    May 1, 2008, 00:00

  • PMS24 RESOURCE UTILIZATION AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS-AN ANALYSIS OF 2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA

    May 1, 2008, 00:00

  • PMC49 TRANSLATING HETEROGENEITY BIAS FROM HEALTH STATUS IN OUTCOMES STUDIES-USING LATENT CLASS CLUSTER ANALYSIS AND LONGITUDINAL DATA

    May 1, 2008, 00:00

  • PMC39 A COMPREHENSIVE PARADIGM TO ESTIMATE MINIMAL CLINICALLY IMPORTANT DIFFERENCES (MCID)

    May 1, 2008, 00:00

  • PHP57 FACTOR ANALYSIS OF PHARMACISTS PERCEIVED BARRIERS TO PROVISION OF MEDICATION THERAPY MANAGEMENT SERVICES (MTMS) IN WEST VIRGINIA

    May 1, 2008, 00:00

  • PUK14 INPATIENT COSTS AND CLINICAL OUTCOMES OF S. AUREUS BLOODSTREAM AND NON-BLOODSTREAM INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE- FINDINGS FROM A MULTI-CENTER TRIAL

    May 1, 2008, 00:00

  • PCV10 EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON CHD EVENTS IN A SECONDARY PREVENTION POPULATION WITH HIGH NON-HDL CHOLESTEROL

    May 1, 2008, 00:00

  • PCN13 BUDGET IMPACT ANALYSIS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CANADA

    May 1, 2008, 00:00

  • PRS37 CONCURRENT ASTHMA CONTROLLER MEDICATION POSSESSION PROFILES IN AN ADULT MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PUK16 COMPARATIVE ECONOMIC EVALUATION OF DUTASTERIDE VERSUS FINASTERIDE FOR MEDICARE-AGED MEN WITH BENIGN PROSTATIC HYPERPLASIA

    May 1, 2008, 00:00

  • PSS6 COST-EFFECTIVENESS OF INTERMITTENT VS. CONTINUOUS ANTI-TNF ALPHA THERAPY IN PLAQUE PSORIASIS

    May 1, 2008, 00:00

  • PMS38 ESTIMATING WORK PRODUCTIVITY- EFFECTS OFTRAMADOL EXTENDED-RELEASE TREATMENT

    May 1, 2008, 00:00

  • PMH37 UNITED KINGDOM COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA- DIABETES AND CORONARY HEART DISEASE RISK PROJECTIONS (STAR STUDY)

    May 1, 2008, 00:00

  • PHC2 A COMPARISON OF COSTS ASSOCIATED WITH SPINAL SURGERIES BY CHOICE OF FIBRIN SEALANT

    May 1, 2008, 00:00

  • PRS23 PARTICIPANTS EXPERIENCE OF ASTHMA- RESULTS FROM A FOCUS GROUP STUDY

    May 1, 2008, 00:00

  • PCV59 THE COST AND EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR LIPID-LOWERING AND ANTIHYPERTENSIVE DRUGS

    May 1, 2008, 00:00

  • PHP70 PHYSICIANS KNOWLEDGE OF LABELED DRUG INDICATIONS AND ATTITUDES REGARDING OFF-LABEL USE- RESULTS OF A NATIONAL SURVEY OF GENERAL INTERNISTS AND PSYCHIATRISTS

    May 1, 2008, 00:00

  • PCV29 A COST-EFFECTIVENESS ANALYSIS OF TREATMENT TO LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL GOAL IN HIGH-RISK PATIENTS BASED UPON THE 2004 NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) GUIDELINE UPDATE

    May 1, 2008, 00:00

  • PIN28 A REALISTIC-AGE-STRUCTURED, DETERMINISTIC, COMPARTMENTAL. TRANSMISSION MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF VACCINATION AGAINST SEASONAL INFLUENZA

    May 1, 2008, 00:00

  • PND39 PATIENT- AND PHYSICIAN-ASSESSED FUNCTIONAL DISABILITY IN PATIENTS TREATED WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PHC3 COST-EFFECTIVENESS MODELING OF DENTAL IMPLANT 1ST LINE STRATEGY VERSUS BRIDGE

    May 1, 2008, 00:00

  • PCN32 COST-EFFECTIVENESS ANALYSIS OF AN HPV-16/18 PROPHYLACTIC CERVICAL CANCER VACCINE IN A SETTING OF EXISTING SCREENING IN PORTUGAL-RESULTS FROM A MATHEMATICAL MODEL

    May 1, 2008, 00:00

  • PCN12 USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS- A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVE

    May 1, 2008, 00:00

  • PHP45 COMMON DRUG REVIEW (CDR) RECOMMENDATIONS- DOES COST-EFFECTIVENESS MATTER?

    May 1, 2008, 00:00

  • PRS27 INTERPRETING CLINICAL TRIALS RESULTS FOR THE ONSET OF EFFECT QUESTIONNAIRE- METHODS AND RESULTS OF A DELPHI PANEL

    May 1, 2008, 00:00

  • WH4 PROBIOTICS IN PREGNANCY-A SYSTEMATIC REVIEWAND META-ANALYSIS OF THE SAFETY OF LACTOBACILLUS, BIFIDOBACTERIUM AND SACCHAROMYCES

    May 1, 2008, 00:00

  • PCV94 PREDICTING HIGH COSTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE

    May 1, 2008, 00:00

  • PMH74 IMPACT OF ALTERNATIVE TREATMENTS ON POST TREATMENT COSTS FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • PIH30 PRIVATE HEALTH INSURANCE VS. MEDICAID COVERAGE- DISPARITIES IN PROCESS OF CARE MEASURES

    May 1, 2008, 00:00

  • PMC55 MATRIX MODEL FOR DETERMINING A DRUGS HEALTH ECONOMIC FOCUSTO OPTIMIZE ITS ECONOMICVIABILITY

    May 1, 2008, 00:00

  • PRS25 VALIDATION OF CLAIMS-BASED PERSISTENT ASTHMA SEVERITY CLASSIFICATION

    May 1, 2008, 00:00

  • PSS25 PHARMACOECONOMIC STUDY OF WET AGE-RELATED MACULAR DEGENERATION (AND)TREATMENT IN MEXICO

    May 1, 2008, 00:00

  • PDB48 LOST PRODUCTIVITY ASSOCIATED WITH TYPE I AND TYPE 2 DIABETES IN A COMMERCIALLY-INSURED POPULATION

    May 1, 2008, 00:00

  • PHP50 A TYPOLOGY OF AFRICAN AMERICAN COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AND ITS CORRELATES FROM THE ANDERSEN HEALTH CARE UTILIZATION MODEL

    May 1, 2008, 00:00

  • AC3 DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTSWITH INSOMNIA

    May 1, 2008, 00:00

  • PCN87 USE OF PHARMACOECONOMIC MESSAGES IN ONCOLOGY PROMOTIONAL MATERIALS

    May 1, 2008, 00:00

  • PUK25 DIALYSIS FACILITY CHARACTERISTICS INFLUENCE THE USE OF HOME DIALYSIS IN THE U.S.

    May 1, 2008, 00:00

  • PMC23 PREDICTION MODELS FOR TRANSITIONS IN THE ELDERLY USING ADMINISTRATIVE CLAIMS

    May 1, 2008, 00:00

  • PHP65 THE ROLE OF THE ACADEMY OF MANAGED CARE PHARMACY (AMCP) FORMAT IN MANAGED CARE FORMULARY AND COVERAGE DECISIONMAKING

    May 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157 (current)
  • 158
  • 159
  • 160
  • »